Hepion Pharmaceuticals, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) is a clinical-stage biopharmaceutical company headquartered in Edison, New Jersey, and originally spun off from Synergy Pharmaceuticals in 2014 as ContraVir Pharmaceuticals. The company utilizes its proprietary AI-POWR platform, which integrates artificial intelligence, machine learning, and deep learning to advance therapeutic drug development targeting non-alcoholic steatohepatitis (NASH, now termed MASH), fibrotic diseases, hepatocellular carcinoma (HCC), viral hepatitis, idiopathic pulmonary fibrosis, and other chronic liver conditions. Its lead product candidate, rencofilstat (formerly CRV431), is a potent cyclophilin inhibitor designed to address multiple disease pathways including fibrosis, inflammation, steatosis, and tumor burden reduction; rencofilstat received U.S. FDA Fast Track designation for NASH in 2021 and Orphan Drug designation for HCC in 2022, and has advanced through Phase 2 trials such as AMBITION, ALTITUDE-NASH, and ASCEND-NASH, demonstrating improvements in liver function, stiffness, and biomarkers prior to trial wind-down. The company operates primarily in the United States with a focus on global patient populations affected by chronic liver diseases impacting roughly half a billion people worldwide. Recent developments include the termination of a proposed merger with Pharma Two B Ltd. in December 2024 after initiating wind-down of the ASCEND-NASH trial in April 2024 and a strategic restructuring in December 2023 to preserve capital; in 2025, Hepion executed a 1-for-35 reverse stock split in March, raised $9.0 million via public offering in January, received Nasdaq delisting notification in May, entered a binding letter of intent in May with New Day Diagnostics to commercialize diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC, appointed Dr. Kaouthar Lbiati as interim CEO in June, and successfully applied for OTCQB listing in June.
MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
Hepion Pharmaceuticals Announces Reverse Stock Split
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.
Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds
Hepion Pharmaceuticals to Present at NASH-TAG 2024
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH' Liver Function Trial of Rencofilstat
Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model